Karim Mikhail, Amarin CEO
June 10, 2022 02:51 PM EDTUpdated 04:26 PM
Pharma

UK’s NICE grants ac­cess to Amar­in's cho­les­terol drug amid US staff cuts

Tyler Patchen

News Reporter

The UK’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence, or NICE, on Fri­day agreed to cov­er Amarin’s con­tro­ver­sial cho­les­terol drug Vas­cepa, amidst tur­bu­lence for Amarin …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times